Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Prescient Therapeutics Limited ( (AU:PTX) ).
Prescient Therapeutics Limited announced a change in the director’s interest, with Director James Campbell acquiring 750,000 fully paid ordinary shares through participation in a Share Purchase Plan. This acquisition increases his indirect holdings via Fusion Biosciences Pty Ltd, reflecting a significant vote of confidence in the company’s strategic direction and potential growth prospects.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on the development of targeted therapies for cancer treatment. The company leverages its expertise in oncology to advance innovative therapeutic solutions aimed at improving patient outcomes.
Average Trading Volume: 1,289,921
Technical Sentiment Signal: Sell
Current Market Cap: A$40.06M
For an in-depth examination of PTX stock, go to TipRanks’ Overview page.